EC approves subcutaneous RYBREVANT in combination with LAZCLUZE

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European Commission marketing authorization of the subcutaneous formulation of RYBREVANT, in combination with LAZCLUZE, for the first-line treatment of adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations. Additionally, it is approved as a monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy. Subcutaneous amivantamab is co-formulated Halozyme’s ENHANZE drug delivery technology